Orexo is Committed to Supporting Patients with Opioid Use Disorder (OUD)
Click here for more information.
Who We Are
- We are Orexo’s US operation, and we are integral to bringing innovative treatment solutions to patients in the United States.
- Our organization is focused on commercializing ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII) in the US market.
- We also offer digital mental health programs designed to help patients with Opioid Use Disorder (OUD) and alcohol management.
- We have a strong, experienced US Leadership Team.
Who We Serve
- Patients with opioid dependence or OUD
- Patients with addiction and alcohol abuse
- Patients with mental illnesses looking to increase their access to healthcare
What We Offer
Through healthcare professionals, we offer:
- ZUBSOLV (buprenorphine and naloxone) sublingual tablets (CIII). Please see full Prescribing Information here.
We also offer the following digital mental health programs developed in collaboration with GAIA (MODIA®) and solely by GAIA (Vorvida®):
- MODIA is designed to help patients with OUD develop behavioral coping skills and provide educational information, reminders, and motivational guidance.
- Vorvida is designed for individuals who want to reduce their alcohol use and manage their drinking behavior.
Orexo Digital Health Disclaimers
MODIA is not a healthcare provider and does not provide medical advice, diagnosis, or specific treatment, and is marketed under FDA enforcement discretion.
Vorvida is marketed as a general wellness product. Vorvida is not a healthcare provider and does not provide medical advice, diagnosis, or treatment.
Orexo US, Inc. Corporate Governance
For compliance issues or concerns, please submit a report via the link below or call +1 (844) 251-4251.